Insider Purchases: Inside the Buy
Tag: CEO Stock Purchase
The Great Data Detective: Is Varonis Solving Crimes or Just Finding Them?
Varonis’s stock chart looks like a crime scene—but insiders are buying, institutions are piled in, and the company sits at the center of AI data security. Is VRNS a value trap… or a comeback case file in the making?
Monro’s Pivot: From Aggressive Expansion to Margin Optimization
Monro cut 145 underperforming stores, lifted margins, and still pays a 5.5% dividend—while the CEO and Carl Icahn buy shares. A slow-burn, high-yield turnaround story in an aging-car economy.
Lumen Technologies: The Turnaround Nobody Believed (But the CEO Keeps Adding)
Lumen was left for dead—then the CEO kept buying, debt vanished, and AI demand showed up. A fun, honest look at LUMN’s comeback, risks, and why the stock may need a breather before the next sprint.
Enphase Energy: The Comeback Nobody Believed (But the CEO Keeps Buying)
Enphase Energy fell hard after its solar boom—but the CEO keeps buying, institutions still dominate the float, and shorts are piled in. Here’s why ENPH might be starting to sync back in—and what investors should really watch. 🌞🔋
CEO Buys Shares of International Paper: Toilet, Shredded, or Stationery?
International Paper is mid-divorce, mid-restructuring — and its CEO just bought $2M of stock. A messy, event-driven value play with real risk and real conviction.
CEO Purchases Abbott Shares, But the Stock Carries Risks
Abbott’s CEO just stepped in with a $2M insider buy — analysts are bullish, shorts are scarce, and institutions remain locked in. Tempting? Yes. Risk-free? Not quite.
CEO Buys More of This Warren Buffett Favorite: Ally Financial Is Up 30% Since Our Bullish Call — Buy More?
Ally Financial is up nearly 30% since our bullish call — and the CEO just bought almost $1M more stock. With Buffett still onboard, analysts bullish, and valuation cheap, this value story may not be done.
Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!
XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.
Insiders Buy Shares Again; Can Energizer Regain Power?
Energizer insiders keep loading up on shares while institutions hold more than the float. Meanwhile, guidance dips and tariffs bite. Is ENR a contrarian deep-value gem ready to recharge — or a battery running low? Here’s the fun, funny breakdown. 🔋🐰
Insiders Purchase Shares of Goosehead Insurance — Should You Buy, Duck, or Just Take a Gander?
Insiders are loading up on Goosehead Insurance shares — and institutions can’t get enough. With strong growth but real risks, is this goose ready to fly… or cooked? Here’s the fun, smart breakdown. 🪿📈🔥